Do Insurers Spend Too Much on Administration and Too Little on Care?

Publication
Article
Oncology & Biotech NewsDecember 2009
Volume 0

Articles in this issue
Amgen Honored for Best Pipeline & Best New Drug
Do Insurers Spend Too Much on Administration and Too Little on Care?
The Effect of New Treatments on Cancer-related Bone Loss
Exercise Maintains Function, Improves QoL for Patients With Lymphoma
Continuing Education Opportunities on the Web
Ramucirumab (IMC-1121B): A Novel Fully Human Monoclonal Antibody that Targets VEGFR-2
News Briefs & FDA Updates
News & Opinion
Decline in Cancer Deaths No Reason to Get Complacent
Related Videos
Related Content
Lora Markley, Director of Regional Managed Care for The US Oncology Network

Quality Over Quantity: What Concierge Medicine Can Offer to Patients With Cancer and Employers

April 19th 2024
Article
Sorting Through Sexism, Guilt, and Motherhood in Medicine

Sorting Through Sexism, Guilt, and Motherhood in Medicine

January 27th 2022
Podcast
Susan D. Klugman, MD, director, reproductive and medical genetics, program director, medical genetics and genomics, Montefiore Einstein; professor, obstetrics and gynecology and women’s health, Albert Einstein College of Medicine

Patient Insurance Status and Out-of-Pocket Costs Affect Genomic Testing Frequency

April 2nd 2024
Article
Gilbert on Gaining New Ground at Vanderbilt

Gilbert on Gaining New Ground at Vanderbilt

January 3rd 2022
Podcast
Maurie Markman, MD

Public Trust in Science and the Future of Cancer Care Is Crucial

January 12th 2024
Article
Jason Westin, MD

Westin Testifies to Senate Finance Committee on Cancer Drug Shortage

December 5th 2023
Article